{"disease":{"id":"induction-therapy","name":"induction therapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04384627","title":"Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":445,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05385432","title":"Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":244,"lead_sponsor_name":"University Hospital, Tours","has_results":false},{"nct_id":"NCT06811844","title":"Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT07143877","title":"Prognostic Impacts of Lipid Profile and BMI in Adult AML","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT04087967","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":162,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04446130","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05832320","title":"Optimum Induction Therapy of Low-risk APL","phase":"NA","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06421376","title":"Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05114707","title":"Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04083911","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05170542","title":"The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05397769","title":"Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07085234","title":"Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT07091305","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT04539600","title":"Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":23,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04473716","title":"Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06093438","title":"Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT03989713","title":"Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Prof. Dr. Richard F Schlenk","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}